CombiGene Third Quarter 2023 Earnings: kr0.42 loss per share (vs kr0.20 profit in 3Q 2022)

CombiGene (STO:COMBI) Third Quarter 2023 Results

Key Financial Results

• Revenue: kr1.17m (down 91% from 3Q 2022).
• Net loss: kr8.40m (down by 313% from kr3.95m profit in 3Q 2022).
• kr0.42 loss per share (down from kr0.20 profit in 3Q 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

CombiGene shares are down 1.9% from a week ago.

Risk Analysis

Be aware that CombiGene is showing 3 warning signs in our investment analysis that you should know about...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.